

Monoclonal Antibodies

COMPILED



Free E-Book by FitDocMed

All Rights reserved @ FitDocMed

India's Most Affordable Institute for NEETPG

INICET FMGE

Visit www.fitdocmed.com

NAME OF DRUG	CLASS OF DRUGS	USES
DENILEUKIN DIFTOK	IL-2 IMMUNOTOXIN	CUTANEOUS T CELL LYMPHOMA
GENTUXUMAB OZOGAMYCIN	ANTI CD-33 IMMUNOTOXIN	CD33 + AML
BRENTUXIMAB VEDOTIN	ANTI CD-30 IMMUNOTOXIN	CLL
INOTUZUMAB OZOGAMYCIN	ANTI CD-22 IMMUNOTOXIN	RESISTANT ALL
MOXETUMOMAB PASUDOTOX	ANTI CD-22 IMMUNOTOXIN	HAIRY CELL LEUKEMIA
TAGRAKOF USP	IL-3 IMMUNOTOXIN	BLASTIC PLASMACYTOID DENDRITIC CELL NEOPLASIA
BORTEZOMIB	PROTEASOME INHIBITORS	MULTIPLE MYELOMA, MANTLE CELL LYMPHOMA MULTIPLE MYELOMA MULTIPLE MYELOMA
CARFILZOMIB	PROTEASOME INHIBITORS	
IXAZOMIB	PROTEASOME INHIBITORS	
PALBOCICLIB	CDK 4/6 INHIBITORS	ER / PR +VE BREAST CANCER
ABEMACICLIB	CDK 4/6 INHIBITORS	ER / PR +VE BREAST CANCER
RIVOCCICLIB	CDK 4/6 INHIBITORS	ER / PR +VE BREAST CANCER
IPILUMUMAB	CTLA4 INHIBITORS	BRAF -VE MALIGNANT MELANOMA
TREMELIMUMAB	CTLA4 INHIBITORS	BRAF -VE MALIGNANT MELANOMA
PENBROLOZUMAB	POLY RECEPTOR INHIBITORS	BRAF -VE MALIGNANT MELANOMA
NIVOLUMAB	POLY RECEPTOR INHIBITORS	BRAF -VE MALIGNANT MELANOMA
ATEZOLIZUMAB	POLY LIGAND INHIBITORS	NON SMALL CELL LUNG CANCER, UROTHELIAL CANCER
DURVALUMAB	POLY LIGAND INHIBITORS	UROTHELIAL CANCER
AVELUMAB	POLY LIGAND INHIBITORS	MERKEL CELL CANCER, UROTHELIAL CANCER
CEMEPILUMAB	POLY LIGAND INHIBITORS	SQUAMOUS CELL CARCINOMA OF SKIN & LUNG
ERDAFTINIB	FGFR TYROSINE KINASE INHIBITOR	METASTATIC UROTHELIAL CANCER
SONIDEGIB	HEDGEHOG PATHWAY INHIBITOR	BASAL CELL CANCER
GLASDEGIB	HEDGEHOG PATHWAY INHIBITOR	AML
VISMODEGIB	HEDGEHOG PATHWAY INHIBITOR	METASTATIC / RELAPSED BASAL CELL CARCINOMA
OLAPARIB	POLY ADP RIBOSE POLYMERASE INHIBITOR	BRCA +VE OVARY/EPITHOPIAN TUBE/PRIMARY PERITONEAL CANCER

BOSUTINIB	2nd GEN BCR-ABL TYROSINE KINASE INHIBITORS	CML
DASATINIB	2nd GEN BCR-ABL TYROSINE KINASE INHIBITORS	CML
NILOTINIB	2nd GEN BCR-ABL TYROSINE KINASE INHIBITORS	CML
PONATINIB	3rd GEN BCR-ABL TYROSINE KINASE INHIBITORS	CML WITH T315I MUTATION
REGORAFENIB	VEGFR2-TIE2 DUAL TYROSINE KINASE INHIBITORS	GIST
IBRUTINIB	BRUTON'S TYROSINE KINASE INHIBITOR	CLL, WALDENSTROM MACROGLOBULINEMIA, MANTLE CELL LYMPHOMA, MARGINAL ZONE LYMPHOMA
ACALIBRUTINIB	BRUTON'S TYROSINE KINASE INHIBITOR	IBRUTINIB RESISTANT MANTLE CELL LYMPHOMA
CRIZOTINIB	ALK INHIBITORS	ALK +VE NON SMALL LUNG CANCER
ALCETINIB	ALK INHIBITORS	ALK +VE NON SMALL LUNG CANCER
BRIGATINIB	ALK INHIBITORS	ALK +VE NON SMALL LUNG CANCER
CERTINIB	ALK INHIBITORS	ALK +VE NON SMALL LUNG CANCER
LORLATINIB	ALK INHIBITORS	ALK +VE NON SMALL LUNG CANCER
MIDOSTAURIN	FN3S LIKE TYROSINE KINASE INHIBITORS	AML, MASTOCYTOSIS, MAST CELL LEUKEMIA
GLITEUTINIB	FN3S LIKE TYROSINE KINASE INHIBITORS	AML
VENMURAFENIB	BRAF KINASE INHIBITOR	BRAF +VE MELANOMA
DABRAFENIB	BRAF KINASE INHIBITOR	BRAF +VE MELANOMA
ENCORAFENIB	BRAF KINASE INHIBITOR	METASTATIC / UNRESECTABLE MELANOMA
TRAMETINIB	MEK 1/2 INHIBITOR	MELANOMA
BINIMETINIB	MEK 1/2 INHIBITOR	METASTATIC / UNRESECTABLE MELANOMA
COBIMETINIB	MEK 1/2 INHIBITOR	MELANOMA
IDELALISIB	PI3K INHIBITOR	CLL, NHL
DUVELISIB	PI3K INHIBITOR	CLL, NHL
RITUXIMAB	ANTI CD-20 MAB	CLL, NHL, ALMA, TTP, MYASTHENIA GRAVIS, ITP, SLE, RHEUMATOID ARTHRITIS, MULTIPLE SCLEROSIS
OFATUMUMAB	ANTI CD-20 MAB	RITUXIMAB RESISTANT CLL

ADUCANUMAB	ANTI β AMYLOID MAB	ALZHEIMERS DISEASE
SOLANEZUMAB	ANTI β AMYLOID MAB	ALZHEIMERS DISEASE
DENOSUMAB	ANTI RANK LIGAND MAB	OSTEOPOROSIS, HYPERPARATHYROIDISM, GIANT CELL TUMOUR
ROMOSOSUMAB	ANTI SCLEROSTIN MAB	POST MENOPAUSAL OSTEOPOROSIS
BLOSOSUMAB	ANTI SCLEROSTIN MAB	POST MENOPAUSAL OSTEOPOROSIS
EVOLUCUMAB	ANTI PCSK-9 MAB	ATHEROSCLEROSIS / HYPERCHOLESTROLEMIA
ALIROCUMAB	ANTI PCSK-9 MAB	ATHEROSCLEROSIS / HYPERCHOLESTROLEMIA
ABOXIMAB	ANTI GP-1b/IIa MAB	INHIBIT PLATELET AGGREGATION
IDARUCIZUMAB	ANTI-DABIGATRAN	REVERSAL AGENT FOR DABIGATRAN
ECULIZUMAB	ANTI C5 COMPLEMENT PROTEIN	PNH, ATYPICAL HUS, HEMOPHILIA
RAVULIZUMAB	ANTI C5 COMPLEMENT PROTEIN	PNH, ATYPICAL HUS
DIRIDAVUMAB	ANTI HEMAGGLUTININ	INFLUENZA A
BAVITUXIMAB	ANTI PHOSPHATIDYL SERINE MAB	HEPATITIS C
PALVIZUMAB	ANTI RSV PROTEIN F	RESPIRATORY SYNCYTIAL VIRUS (RSV)
IBALIZUMAB	ANTI CD-4 MAB	HIV
OBILTOXAXIMAB	ANTI-TOXIN MAB	ANTHRAX
RAXIBACUMAB	ANTI-TOXIN MAB	ANTHRAX
BEZLOTOXUMAB	ANTI - CLOSTRIDIUM DIFFICILE TOXIN B MAB	PSEUDOMEMBRANOUS ENTEROCOLITIS
ACTOXUMAB	ANTI - CLOSTRIDIUM DIFFICILE TOXIN A MAB	PSEUDOMEMBRANOUS ENTEROCOLITIS
IMICROMAB	ANTI CARDIAC MYOSIN MAB	DIAGNOSIS - MYOCARDIAL INFARCT IMAGING
FANOLESOMAB	ANTI CD-15 MAB	DIAGNOSIS - APPENDICITIS IMAGING
VOTUMUMAB	ANTI CYTOKERATIN TUMOR ASSOCIATED ANTIGEN MAB	DIAGNOSIS - COLORECTAL CANCER IMAGING
ARCTUNOMAB	ANTI CEA ANTIGEN MAB	DIAGNOSIS - COLORECTAL CANCER IMAGING
SULESOMAB	ANTI NCA 90 MAB	DIAGNOSIS - OSTEOMYELITIS IMAGING
NOFETUMOMAB	ANTI CARCINOMA ASSOCIATED ANTIGEN MAB	DIAGNOSIS - SMALL CELL LUNG CANCER IMAGING

ORINUTUZUMAB	ANTI CD-20 MAB	RITUXIMAB RESISTANT CLL
OCRELIZUMAB	ANTI CD-20 MAB	RHEUMATOID ARTHRITIS, MULTIPLE SCLEROSIS
IBERITUMOMAB	ANTI CD-20 MAB	NHL
TOSTUMOMAB	ANTI CD-20 MAB	NHL
MOGAMULUZUMAB	ANTI CCR-4 MAB	MYCOSIS FUNGOIDES / SEZARY SYNDROME
DARATUMUMAB	ANTI CD-38 MAB	MULTIPLE MYELOMA
ISATUMIMAB	ANTI CD-38 MAB	MULTIPLE MYELOMA
NATALIZUMAB	ANTI α4β1 INTEGRIN MAB	MULTIPLE SCLEROSIS, CROHN'S DISEASE
VEDOLIZUMAB	ANTI α4β1 INTEGRIN MAB	ULCERATIVE COLITIS, CROHN'S DISEASE
EPRATUZUMAB	ANTI CD-22 MAB	SLE
BEILUMAB	ANTI B-LYMPHOCYTE STIMULATOR MAB	SLE
ALEMTUZUMAB	ANTI CD-52 MAB	LOW GRADE LYMPHOMA, MULTIPLE SCLEROSIS
BLINATUMUMAB	BISPECIFIC T CELL ENGAGER (ANTI CD3 & CD19)	RESISTANT ALL
DINUTUMAB	ANTI GANGLIOSIDE (GD2) MAB	NEUROBLASTOMA
CATUMAXUMAB	ANTI CD-3, ANTI EPCAM MAB	MALIGNANT ASCITES IN OVARIAN & GASTRIC CARCINOMA
CANAKINUMAB	ANTI IL-1β	JUVENILE IDIOPATHIC ARTHRITIS, CRYOPYRIN ASSOCIATED PERIODIC SYNDROME (CAPS), COLD AUTO INFLAMMATORY SYNDROME
ALDESLEUJIN	IL-2 ANALOGUE	RENAL CELL CANCER, MALIGNANT MELANOMA
BASILIXIMAB	ANTI IL-2 RECEPTOR, ANTI CD-25 MAB	PREVENTION OF TRANSPLANT REJECTIONS
DACLIZUMAB	ANTI IL-2 RECEPTOR, ANTI CD-25 MAB	PREVENTION OF TRANSPLANT REJECTIONS, MULTIPLE SCLEROSIS
MUROMONAB	ANTI IL-3 MAB	PREVENTION OF TRANSPLANT REJECTIONS
OMALIZUMAB	ANTI IgE MAB	ASTHMA
RESLIZUMAB	ANTI IL-5 MAB	ASTHMA
MEPOLIZUMAB	ANTI IL-5 MAB	ASTHMA
BENRALIZUMAB	ANTI IL-5 MAB	ASTHMA
LEBRIKIZUMAB	ANTI IL-13 MAB	ASTHMA
DUPILUMAB	ANTI IL-4 RECEPTOR α MAB	ATOPIC DERMATITIS, ASTHMA

NIRAPARIB	POLY ADP RIBOSE POLYMERASE INHIBITOR	BRCA +VE OVARY/TALLOPIAN TUBE/PRIMARY PERITONEAL CANCER
TALAZOPARIB	POLY ADP RIBOSE POLYMERASE INHIBITOR	BRCA +VE BREAST CANCER
CETUXIMAB	ANTI EGFR MAB	HEAD & NECK CANCER, COLON CANCER
PANITUMUMAB	ANTI EGFR MAB	HEAD & NECK CANCER, COLON CANCER
NECTINUMAB	ANTI EGFR MAB	NON SMALL CELL LUNG CANCER
NIMOTUZUMAB	ANTI EGFR MAB	HEAD & NECK CANCER
ERLOTINIB	EGFR TYROSINE KINASE INHIBITORS	EGFR +VE PANCREATIC CANCER, NON SMALL CELL LUNG CANCER
GEFITINIB	EGFR TYROSINE KINASE INHIBITORS	NON SMALL CELL LUNG CANCER
AFATINIB	EGFR TYROSINE KINASE INHIBITORS	NON SMALL CELL LUNG CANCER
OSEMIRTINIB	EGFR TYROSINE KINASE INHIBITORS	NON SMALL CELL LUNG CANCER
DACOMITINIB	EGFR TYROSINE KINASE INHIBITORS	NON SMALL CELL LUNG CANCER
OLARATUMAB	ANTI PDGFR- α MAB	SOFT TISSUE SARCOMA
PERTUZUMAB	ANTI HER2 MAB	HER2 +VE BREAST CANCER / GASTRIC CANCER
TRASTUZUMAB	ANTI HER2 MAB	HER2 +VE BREAST CANCER / GASTRIC CANCER
LAPATINIB	HER2 TYROSINE KINASE INHIBITORS	TRASTUZUMAB RESISTANT HER2 +VE BREAST CANCER
NEPASTINIB	HER2 TYROSINE KINASE INHIBITORS	TRASTUZUMAB RESISTANT HER2 +VE BREAST CANCER
BEVACIZUMAB	ANTI VEGF MAB	RENAL CELL CANCER, DIABETIC RETINOPATHY
RANIBIZUMAB	ANTI VEGF MAB	ARMO, CHOROIODAL NEOVASCULARIZATION
RANUCIRUMAB	ANTI VEGF MAB	GASTRIC CANCER, COLON CANCER, NON SMALL CELL LUNG CANCER
BROLUCIZUMAB	ANTI VEGF MAB	DIABETIC RETINOPATHY
PEGAPTINIB	VEGF TYROSINE KINASE INHIBITORS	DIABETIC RETINOPATHY
SUNITINIB	VEGF TYROSINE KINASE INHIBITORS	RENAL CELL CANCER, GIST, PANCREATIC CANCER
SORAFENIB	VEGF TYROSINE KINASE INHIBITORS	HEPATOCELLULAR CARCINOMA
AXITINIB	VEGF TYROSINE KINASE INHIBITORS	RENAL CELL CANCER
PAZOPANIB	VEGF TYROSINE KINASE INHIBITORS	SOFT TISSUE SARCOMA
VANDETANIB	VEGF TYROSINE KINASE INHIBITORS	MEDULLARY THYROID CANCER
LENVATANIB	VEGF TYROSINE KINASE INHIBITORS	MEDULLARY THYROID CANCER
IMATINIB	BCR-ABL TYROSINE KINASE INHIBITORS	CML, GIST

Introducing

NEETPG Test Series




Target NEETPG March 2024 Exam

Includes :

- Subject Wise Test
- Clinical Pattern Test
- NEETPG PYQ Test
- INICET PYQ Test
- Image Based Test
- Mini Mock Test
- NEETPG Grand Test
- Topic Wise Test
- Free NEETPG Last Minute • Revision E- Book

Early Bird Offer

~~₹999~~ ₹299



FitDocMed

Proudly India's Most Affordable
institute for NEETPG INICET FMGE



www.fitdocmed.com

Visit www.fitdocmed.com



Target FMGE 2023



FMGE TEST SERIES

More than 50+ Test, Proper Explanation, Free PYQ Book,
Telegram Based

Enroll Now

SAVE MORE

Visit www.fitdocmed.com